On November 10, the 2019 China-Japan Summit Forum on Advanced Medical Care and New Drug R&D Summit Forum & Achievements Transformation Conference was held in Chengdu, Sichuan. Academicians and experts from China and Japan gathered to share cutting-edge information and development trends in the biomedical industry. He Wei, vice-chairman of Chinese People's Political Consultative Conference (CPPCC), Yin Li, deputy secretary of the CPC Sichuan Provincial Committee and governor of Sichuan Province, Jiao Hong, director of State Drug Administration, and Daisaku Sato, director of Japan's Pharmaceuticals and Medical Devices Agency (PMDA) attended the meeting and addressed at the opening ceremony.
He Wei congratulated on the convening of the conference, noting that since the beginning of 21st century, biotechnology has been continuously breaking through, which not only supports the development of life science, but also promotes the rapid development of biomedical industry. Enhancing human health is the fundamental direction and important task for the development of biomedical industry. Strengthening scientific and technological innovation is an important driving force for the development of biomedical industry. Facilitating win-win cooperation is the path guarantee for the development of bio-pharmaceutical industry. Japan will display and transform 400 advanced medical technologies and biomedical products that have entered clinical research stage at this conference, while China will provide more than 500 cutting-edge technological achievements, which will surely contribute to deepening cooperation between the two sides, improve the efficiency of transformation of achievements, and strengthen the medical industry cluster. It is hoped that the two sides will jointly seize this important opportunity and work hard to realize complementary advantages and win-win cooperation in the biomedical industry of the two countries.
Yin Li expressed congratulations on behalf of the Sichuan Provincial Government on the convening of the conference, noting that this conference has set up a platform for top experts and scholars in the industry to exchange ideas and gather wisdom, and has built a bridge for well-known enterprises at home and abroad to strengthen synergy and deepen cooperation, which will certainly contribute an important force to the healthy development of the global pharmaceutical industry and the all-round development of medical services. We are willing to listen to the views and suggestions of the participants, learn from Japan's advanced experience in pharmaceutical innovation and transformation, and strengthen technological exchanges and industrial synergy. We sincerely welcome experts to come to Sichuan to conduct academic exchanges, and to give more valuable suggestions and guidance on the innovation and development of Sichuan's pharmaceutical industry. We sincerely hope that entrepreneurs will come to Sichuan for inspection, negotiation, investment and development, share the development opportunities of Sichuan's pharmaceutical industry, and create a healthy and beautiful future for all.
On behalf of State Drug Administration, Jiao Hong congratulated on the convening of the conference, saying that in recent years, the research and development of advanced medical products such as cell therapy, gene therapy and tissue engineering has become one of the most important frontier fields of international medicine. It is believed that this conference will further promote the cooperation between the pharmaceutical industries of China and Japan and promote the commercialization of more high-quality medical achievements. It is hoped that more research institutions and pharmaceutical enterprises will promote the R&D and application of new technologies and products through the international exchange and achievement exhibition platform established by this conference, so as to provide more and better innovative medicines for the people and promote the high-quality development of China's pharmaceutical industry.
Daisaku Sato congratulated the conference on behalf of PMDA and expressed his willingness to work hard to promote the unity and cooperation of production, study and research between China and Japan, to jointly overcome the difficult problems of advanced medical treatment and new drug research and development, and to better benefit the people.
Luo Qiang, mayor of Chengdu, and Masanori Fukushima, director of the Translational Research Center for Medical Innovation, delivered speeches respectively. Tasuku Honjo, winner of the 2018 Nobel Prize in Physiology or Medicine, delivered a video speech.
At the opening ceremony, the launching ceremony of "China-Japan Biomedical Achievement Transformation Express" was also held, and representatives of Chinese and Japanese biomedical enterprises signed strategic cooperation agreements for achievement transformation.
Chen Fang, vice-chairman of the CPPCC, representatives of Chinese and Japanese research institutes, industrial parks, business associations, enterprises and heads of relevant provincial departments attended the conference.
